The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.
Angiogenesis Inhibitors
/ administration & dosage
Diabetic Retinopathy
/ complications
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Ganglion Cysts
/ diagnosis
Humans
Intravitreal Injections
Macula Lutea
/ pathology
Macular Edema
/ complications
Male
Middle Aged
Ranibizumab
/ administration & dosage
Receptors, Vascular Endothelial Growth Factor
/ administration & dosage
Recombinant Fusion Proteins
/ administration & dosage
Retrospective Studies
Time Factors
Tomography, Optical Coherence
/ methods
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
anti-VEGF
cysts
diabetic macular oedema
retinal ganglion cell layer
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
22
10
2018
accepted:
18
04
2019
pubmed:
18
5
2019
medline:
17
3
2020
entrez:
18
5
2019
Statut:
ppublish
Résumé
To investigate the prevalence and impact of ganglion cell layer cysts (GCLC) in patients with diabetic macular oedema (DME) under continuous anti-vascular endothelial growth factor (VEGF) therapy. The clinical findings and spectral domain optical coherence devices of baseline visits and follow-up after 12-24 and 36 months of DME patients under continuous anti-VEGF therapy were retrospectively collected and analysed for the impact of GCLC cysts. Previously established prognostic parameters were also assessed. A total of 110 eyes of 110 DME patients (mean age 64 ± 10 years) were included. At baseline, 17% eyes had GCLC. With GCLC, the best-corrected visual acuity (BCVA) improvement was in mean 8.4 ± 2.4 Early-Treatment-Diabetic-Retinopathy-Study (ETDRS) letters less over the course of 36 months compared to the group lacking GCLC (p = 0.0009). Eyes with GCLC showed 68 ± 23.4 μm less central retinal thickness (CRT) decrease than eyes lacking GCLC (p < 0.0001). In the linear mixed effect models including external limiting membrane disruption, disintegration of inner retinal layer and epiretinal membrane, GCLC remained a statistical significant factor for the outcome parameter CRT, but missed statistical significance for BCVA. Ganglion cell layer cysts (GCLC) seem to impact outcome in DME in patients receiving long-term treatment. This prognostic factor warrants further evaluation in the context of already well-established outcome parameters.
Substances chimiques
Angiogenesis Inhibitors
0
Recombinant Fusion Proteins
0
Vascular Endothelial Growth Factor A
0
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1041-e1047Informations de copyright
© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Abegg M, Dysli M, Wolf S, Kowal J, Dufour P & Zinkernagel M (2014): Microcystic macular edema: retrograde maculopathy caused by optic neuropathy. Ophthalmology 121: 142-149.
Arendt P, Yu S, Munk MR, Ebneter A, Wolf S & Zinkernagel MS (2019): Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration. Retina 39: 27-33.
Barber AJ & Baccouche B (2017): Neurodegeneration in diabetic retinopathy: potential for novel therapies. Vision Res 139: 82-92.
Beck M, Munk MR, Ebneter A, Wolf S & Zinkernagel MS (2016): Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol 167: 10-17.
Bonnin S, Tadayoni R, Erginay A, Massin P & Dupas B (2015): Correlation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edema. Invest Ophthalmol Vis Sci 56: 978-982.
Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Melia M, Peters MA, Rauser ME; Diabetic Retinopathy Clinical Research Network (2017): Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab. Ophthalmology 124: 431-439.
Byeon SH, Chu YK, Hong YT, Kim M, Kang HM & Kwon OW (2012): New insights into the pathoanatomy of diabetic macular edema: angiographic patterns and optical coherence tomography. Retina 32: 1087-1099.
Cai S & Bressler NM (2017): Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol 28: 636-643.
Chalam KV, Bressler SB, Edwards AR et al. (2012): Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 53: 8154-8161.
Chen X, Zhang L, Sohn EH, Lee K, Niemeijer M, Chen J, Sonka M & Abramoff MD (2012): Quantification of external limiting membrane disruption caused by diabetic macular edema from SD-OCT. Invest Ophthalmol Vis Sci 53: 8042-8048.
Daruich A, Matet A, Moulin A et al. (2018): Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res 63: 20-68.
Das R, Spence G, Hogg RE, Stevenson M & Chakravarthy U (2018): Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmol 136: 202-208.
Diabetic Research Retinopathy Clinical Network, Browning DJ, Glassman AR, Aiello LP et al. (2007): Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114: 525-536.
van Dijk HW, Verbraak FD, Stehouwer M et al. (2011): Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy. Vision Res 51: 224-228.
Ebneter A, Wolf S, Abhishek J & Zinkernagel MS (2016): Retinal layer response to ranibizumab during treatment of diabetic macular edema: thinner is not always better. Retina 36: 1314-1323.
Ip MS, Zhang J & Ehrlich JS (2017): The clinical importance of changes in diabetic retinopathy severity score. Ophthalmology 124: 596-603.
Karst SG, Lammer J, Mitsch C et al. (2018): Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 256: 49-58.
Koyanagi Y, Yoshida S, Kobayashi Y et al. (2018): Visual outcomes based on early response to anti-vascular endothelial growth factor treatment for diabetic macular edema. Ophthalmologica 239: 94-102.
Lala C, Framme C, Wolf- Schnurrbusch UE & Wolf S (2013): Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. Acta Ophthalmol 91: 526-530.
Lee JY, Choi JH, Park KA & Oh SY (2018): Ganglion cell layer and inner plexiform layer as predictors of vision recovery in ethambutol-induced optic neuropathy: a longitudinal OCT analysis. Invest Ophthalmol Vis Sci 59: 2104-2109.
Mane V, Dupas B, Gaudric A et al. (2016): Correlation between cystoid spaces in chronic diabetic macular edema and capillary nonperfusion detected by optical coherence tomography angiography. Retina 36(Suppl 1): S102-S110.
Menke MN, Zinkernagel MS, Ebneter A & Wolf S (2014): Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. Br J Ophthalmol 98: 1197-1200.
Meuer SM, Myers CE, Klein BE et al. (2015): The epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain optical coherence tomography: the beaver dam eye study. Ophthalmology 122: 787-795.
Morales-Fernandez L, Jimenez-Santos M, Martinez-de-la- Casa JM et al. (2018): Diagnostic capacity of SD-OCT segmented ganglion cell complex versus retinal nerve fiber layer analysis for congenital glaucoma. Eye (Lond) 32: 1338-1344.
Mori Y, Suzuma K, Uji A et al. (2016): Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema. Sci Rep 2016(6): 39161.
Munk MR, Bolz M, Huf W, Sulzbacher F, Roberts P, Simader C, Ruckert R & Kiss CG (2013): Morphologic and functional evaluations during development, resolution, and relapse of uveitis-associated cystoid macular edema. Retina 33: 1673-1683.
Munk MR, Kiss CG, Huf W, Montuoro A, Sulzbacher F, Kroh M, Larsen M & Schmidt-Erfurth U (2014): Visual acuity and microperimetric mapping of lesion area in eyes with inflammatory cystoid macular oedema. Acta Ophthalmol 92: 332-338.
Munk MR, Jampol LM, Simader C, Huf W, Mittermuller TJ, Jaffe GJ & Schmidt-Erfurth U (2015): Differentiation of diabetic macular edema from pseudophakic cystoid macular edema by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 56: 6724-6733.
Munk MR, Arendt P, Yu S, Ceklic L, Huf W, Ebneter A, Wolf S & Zinkernagel MS (2018): The impact of the vitreomacular interface in neovascular age-related macular degeneration in a treat-and-extend regimen with exit strategy. Ophthalmol Retina 125: 622-627.
Nesper PL, Scarinci F & Fawzi A (2017): Adaptive optics reveals photoreceptor abnormalities in diabetic macular ischemia. PLoS ONE 12: e0169926.
Parodi Battaglia M, Iacono P, Cascavilla M, Zucchiatti I & Bandello F (2018): A pathogenetic classification of diabetic macular edema. Ophthalmic Res 60: 23-28.
Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS & Aiello LP (2014): Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 132: 1309-1316.
Vujosevic S, Torresin T, Berton M, Bini S, Convento E & Midena E (2017): Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities. Am J Ophthalmol 181: 149-155.
Vujosevic S, Muraca A, Alkabes M, Villani E, Cavarzeran F, Rossetti L & De Cilla S (2019): Early microvascular and neural changes in patients with type 1 and type 2 diabetes mellitus without clinical signs of diabetic retinopathy. Retina 39: 435-445.